BioMarin Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
BioMarin Pharmaceutical has a total shareholder equity of $5.4B and total debt of $594.6M, which brings its debt-to-equity ratio to 11%. Its total assets and total liabilities are $6.9B and $1.4B respectively. BioMarin Pharmaceutical's EBIT is $326.4M making its interest coverage ratio -5.5. It has cash and short-term investments of $930.4M.
Key information
11.0%
Debt to equity ratio
US$594.63m
Debt
| Interest coverage ratio | -5.5x |
| Cash | US$930.44m |
| Equity | US$5.41b |
| Total liabilities | US$1.44b |
| Total assets | US$6.85b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BM8's short term assets ($3.1B) exceed its short term liabilities ($715.7M).
Long Term Liabilities: BM8's short term assets ($3.1B) exceed its long term liabilities ($722.1M).
Debt to Equity History and Analysis
Debt Level: BM8 has more cash than its total debt.
Reducing Debt: BM8's debt to equity ratio has reduced from 27.4% to 11% over the past 5 years.
Debt Coverage: BM8's debt is well covered by operating cash flow (69.7%).
Interest Coverage: BM8 earns more interest than it pays, so coverage of interest payments is not a concern.